Search | IOVS | ARVO Journals

Showing 1 – 20 of 124

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2024

Inhibition of VEGFA induced HUVEC migration via RO-104, a novel trispecific protein

Yixuan Ma; Alina K Sinha; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Ashwin Gupta; Nikhil Gupta; Megana Paidela; Isabel Ray; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1942.

ARVO Annual Meeting Abstract June 2024

Rat Laser CNV Efficacy Studies with the Novel Trispecific Protein RO-104

Alina K Sinha; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Nikhil Gupta; Ashwin Gupta; Megana Paidela; Isabel Ray; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2163.

ARVO Annual Meeting Abstract June 2024

The EC50 binding characteristics of novel trispecific protein, RO-104

Parth Patel; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Alina K Sinha; Nikhil Gupta; Ashwin Gupta; Megana Paidela; Isabel Ray; Yixuan Ma; Jessi Prentice; Ramanath Bhandari; Ramesh Bhatt

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5088.

ARVO Annual Meeting Abstract June 2024

Characterization of the Receptor-Ligand Competition of RO-104 IC50 Potencies

Ashwin Gupta; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Ramesh Bhatt; Parth Patel; Alina K Sinha; Nikhil Gupta; Megana Paidela; Isabel Ray; Yixuan Ma; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):264.

ARVO Annual Meeting Abstract June 2024

Pharmacokinetic Analysis of RO-104 in Rabbit Eye Vitreous

Nikhil Gupta; Li Xu; Peter K Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Ashwin Gupta; Alina K Sinha; Megana Paidela; Isabel Ray; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):263.

ARVO Annual Meeting Abstract June 2024

Population pharmacokinetic modeling and simulation of ocular clearance for aflibercept 8 mg and 2 mg and association with durability of effect

Peter K Kaiser; Kenneth C Turner; Sébastien Bihorel; Joannellyn Chiu; Lutz Harnisch; Jason Chittenden; Thomas Eissing; Joachim Höchel; Torsten Zimmermann; Thomas DiCioccio

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3154.

ARVO Annual Meeting Abstract June 2024

The 18-Month Efficacy of Avacincaptad Pegol in Geographic Atrophy: Pooled Results from GATHER1 and GATHER2

Greggory Gahn; Peter K Kaiser; Arshad M. Khanani; Carl J Danzig; Jeffrey S Heier; Julie Clark; Liansheng Zhu; Hersh Patel; Don Luo; Nikhil Patel; Glenn J Jaffe

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):4400.

ARVO Annual Meeting Abstract June 2024

Oral APX3330, a Ref-1 Inhibitor, Slows Progression of Diabetic Retinopathy on a Binocular DRSS Person-Level Scale

Daniel Su; Jay Stuart Pepose; Barbara Withers; Mitchell G Brigell; Audrey Lazar; Ronil Patel; George Magrath; Peter K Kaiser; David S Boyer

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):958.

ARVO Annual Meeting Abstract June 2024

Assessment of pre-existing anti-drug antibodies (ADAs) in pooled serum against novel trispecific biologic RO-104 analogs

Isabel Ray; Alina K Sinha; Li Xu; Peter M Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Nikhil Gupta; Ashwin Gupta; Megana Paidela; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):715.

ARVO Annual Meeting Abstract June 2024

Binding characteristics of a novel trispecific protein RO-104 to aflibercept

Megana Paidela; Li Xu; Peter M Kaiser; Arshad M. Khanani; Jeffrey S Heier; Jessi Prentice; Parth Patel; Nikhil Gupta; Ashwin Gupta; Alina K Sinha; Isabel Ray; Yixuan Ma; Ramesh Bhatt; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):1950.

ARVO Annual Meeting Abstract June 2024

Impact of adalimumab response on quality of life and mental health of children with juvenile idiopathic arthritis and uveitis

Peter M Kaiser; Megan Quinlan-Waters; Alexandra Duell; Virginia Miraldi Utz; Matthew Schulgit; Kimberly Baynes; Sumit Sharma; Sunil K Srivastava; Sheila T Angeles-Han

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2610.

ARVO Annual Meeting Abstract June 2023

ZETA-1 Phase 2 Trial to Determine the Safety and Efficacy of APX3330: a Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy

Daniel Su; Jay Stuart Pepose; Mark R Kelley; Audrey Lazar; Louis Haddad; Mina Sooch; Mitchell G Brigell; Peter K Kaiser; David S Boyer

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3753.

ARVO Annual Meeting Abstract June 2023

The Characterization of the Ang-2 Arm of a Novel Anti-VEGF-A and Ang-2 Bispecific Protein (RO-101) in Comparison to Faricimab-svoa

Megana Paidela; Li Xu; Parth Patel; John Mitchell Kunzeman; Jessi Prentice; Robert Lowenthal; Mark Barakat; Arshad M. Khanani; Peter K Kaiser; Jeffrey L. Olson; Jeffrey S Heier; Ramanath Bhandari

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):739.

ARVO Annual Meeting Abstract June 2023

U.S. Phase 1 Study of Intravitreal Axitinib Implant (OTX-TKI) for Neovascular Age-related Macular Degeneration

Andrew A Moshfeghi; Arshad M. Khanani; David Aaron Eichenbaum; Charles Clifton Wykoff; Stephen Couvillion; Samantha Xavier; Nathan Steinle; Peter Kaiser; Rabia Gurses Ozden

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):936.

ARVO Annual Meeting Abstract June 2023

Semi-automated choroidal volume metrics utilizing swept source optical coherence tomography in patients with active and inactive sarcoidosis.

Josiah S Holt; Sumit Sharma; Kimberly Baynes; Danielle X Burton; Abel Hamdan; Cindy Chen; Phuoc-Hanh Le; Peter M Kaiser; Careen Lowder; Sunil K Srivastava

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2565.

ARVO Annual Meeting Abstract June 2023

Assessment of swept source optical coherence tomography angiography metrics in uveitis with vascular leakage on ultrawide field fluorescein angiography

Ishan Shah; Sumit Sharma; Kimberly Baynes; Peter M Kaiser; Megan Ann McDonald; Cindy Chen; Phuoc-Hanh Le; Danielle X Burton; Abel Hamdan; Sunil K Srivastava

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2547.

ARVO Annual Meeting Abstract June 2023

Treatment response to avacincaptad pegol by baseline patient characteristics: A prespecified subgroup analysis of the phase 3 GATHER2 study

Carl J Danzig; Peter Kaiser; David Lally; Glenn J Jaffe; Arshad M. Khanani; Charles Clifton Wykoff; Jeffrey S Heier; Justin Tang; Liansheng Zhu; Julie Clark

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):984.

ARVO Annual Meeting Abstract June 2023

Evidence of clonal expansion among vitreous-derived T-cells in birdshot chorioretinopathy: A single cell profiling-based molecular case study

Wen Fury; Sunil K Srivastava; Charles Miller; Christina Adler; Sumit Sharma; Kimberly Baynes; Ashley Lowe; Danielle X Burton; Bolisa Hang; Peter Kaiser; Santiago Patricio Mendez Huergo; Raquel Deering; Min Ni; Yi Wei; Mickey Atwal; Johnathan Weyne

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):429.

ARVO Annual Meeting Abstract June 2023

Imaging Characteristics and Clinical Utility of Half vs Full Dose Ultra-Widefield Fluorescein Angiography

Andrei Szigiato; Sandeep Singh; Margaret Mills; Kimberly Baynes; Sumit Sharma; Careen Lowder; Peter Kaiser; Justis P Ehlers; Sunil K Srivastava

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):3730.

ARVO Annual Meeting Abstract June 2023

Predictors of Response to a Lapse in Anti-VEGF Treatment in Patients with Macular Edema Secondary to Retinal Vein Occlusions

Christopher Maatouk; Jessica C Liu; Peter Alsaloum; Amogh Iyer; Peter Kaiser; Rishi P Singh; Katherine Talcott

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1790.

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Inhibition of VEGFA induced HUVEC migration via RO-104, a novel trispecific protein

Rat Laser CNV Efficacy Studies with the Novel Trispecific Protein RO-104

The EC50 binding characteristics of novel trispecific protein, RO-104

Characterization of the Receptor-Ligand Competition of RO-104 IC50 Potencies

Pharmacokinetic Analysis of RO-104 in Rabbit Eye Vitreous

Population pharmacokinetic modeling and simulation of ocular clearance for aflibercept 8 mg and 2 mg and association with durability of effect

The 18-Month Efficacy of Avacincaptad Pegol in Geographic Atrophy: Pooled Results from GATHER1 and GATHER2

Oral APX3330, a Ref-1 Inhibitor, Slows Progression of Diabetic Retinopathy on a Binocular DRSS Person-Level Scale

Assessment of pre-existing anti-drug antibodies (ADAs) in pooled serum against novel trispecific biologic RO-104 analogs

Binding characteristics of a novel trispecific protein RO-104 to aflibercept

Impact of adalimumab response on quality of life and mental health of children with juvenile idiopathic arthritis and uveitis

ZETA-1 Phase 2 Trial to Determine the Safety and Efficacy of APX3330: a Novel, Oral Ref-1 Inhibitor for the Treatment of Diabetic Retinopathy

The Characterization of the Ang-2 Arm of a Novel Anti-VEGF-A and Ang-2 Bispecific Protein (RO-101) in Comparison to Faricimab-svoa

U.S. Phase 1 Study of Intravitreal Axitinib Implant (OTX-TKI) for Neovascular Age-related Macular Degeneration

Semi-automated choroidal volume metrics utilizing swept source optical coherence tomography in patients with active and inactive sarcoidosis.

Assessment of swept source optical coherence tomography angiography metrics in uveitis with vascular leakage on ultrawide field fluorescein angiography

Treatment response to avacincaptad pegol by baseline patient characteristics: A prespecified subgroup analysis of the phase 3 GATHER2 study

Evidence of clonal expansion among vitreous-derived T-cells in birdshot chorioretinopathy: A single cell profiling-based molecular case study

Imaging Characteristics and Clinical Utility of Half vs Full Dose Ultra-Widefield Fluorescein Angiography

Predictors of Response to a Lapse in Anti-VEGF Treatment in Patients with Macular Edema Secondary to Retinal Vein Occlusions

To View More...

You must be signed into an individual account to use this feature.